search
Back to results

Extension of the Psychometric Validation Study ORCHESTRA in Patients With PAH

Primary Purpose

Pulmonary Arterial Hypertension

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Macitentan
Sponsored by
Actelion
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pulmonary Arterial Hypertension focused on measuring pulmonary arterial hypertension, PAH-SYMPACT, PAH, psychometric instrument

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Signed informed consent prior to any study-mandated procedure.
  2. Patients with PAH who completed the ORCHESTRA study (AC-055-310) as scheduled
  3. Women of childbearing potential (as defined below) must:

    • Have a negative serum pregnancy test at Visit 1 (i.e., Visit 4 of study AC 055 310) and agree to perform monthly serum pregnancy tests.
    • Agree to use two reliable methods of contraception in parallel, from Visit 1 until 1 month after study drug discontinuation (see details below).

      • A female is considered to have childbearing potential unless she meets at least one of the following criteria:

        • Previous bilateral salpingo and/or oophorectomy, or hysterectomy.
        • Premature ovarian failure confirmed by a specialist.
        • Pre-pubescence, XY genotype, Turner syndrome, uterine agenesis.
        • Postmenopausal, defined as 12 consecutive months with no menses without an alternative medical cause.
      • Of the two contraceptive methods that must be used, one must be from Group 1, and one must be from Group 2, defined as follows:

        • Group 1: Oral, implantable, transdermal or injectable hormonal contraceptives, intrauterine devices, female sterilization (tubal ligation or non-surgical sterilization, e.g., permanent contraception with Essure procedure), or partner's sterilization (vasectomy). If a hormonal contraceptive is chosen from this group, it must be taken for at least one month prior to enrollment. Alternatively, if the Essure procedure is chosen as a contraceptive method, a hysterosalpingogram must have been performed to confirm correct location of the microinserts and tubal occlusion (as per manufacturer's recommendations).
        • Group 2: Female or male condoms, diaphragm or cervical cap, any of them in combination with a spermicide.
      • Sexual abstinence, rhythm methods, or contraception by the partner alone are not considered as acceptable methods of contraception for this study.

Exclusion Criteria:

  1. Patients who prematurely discontinued study drug in study AC-055-310.
  2. Females who are lactating or pregnant (positive Visit 1 pregnancy test) or plan to become pregnant during the study.
  3. AST and/or ALT more than 3 X ULN.

Sites / Locations

  • Hôpital Louis Pradel
  • Hôpital Côte de Nacre
  • Hôpital Albert Michallon
  • CHU de Bicêtre
  • CHRU Lille - Hôpital Cardiologique
  • Hôpital Arnaud de Villeneuve
  • Hôpitaux de Brabois
  • Hôpital de Haut Levêque
  • Hôpital Pontchaillou
  • Hôpital Charles Nicolle
  • Hôpital Nord
  • Hôpital Civil
  • Hôpital Larrey
  • Ospedale Sant'Orsola
  • A.O.U.C. Careggi
  • UOC Immunologia Clinica B-PGRM Centro di Riferimento per la Sclerosi Sistemica
  • Centro Per La Diagnosi E La Cura Dell'Ipertensione Polmonare
  • Policlinico G.B. Rossi
  • Hospital General de Alicante
  • Hospital Val Hebron
  • Hospital Clinic
  • Hospital de Cruces
  • Hospital Reina Sofia
  • Hospital Dr Negrin
  • Hospital Universitario Insular Gran Canarias
  • Hospital 12 Octubre
  • Hospital La Paz
  • Hospital Carlos Haya
  • Hospital Son Espases
  • Hospital de Valdecilla
  • Hospital Virgen del Rocio
  • Hospita General U. Valencia

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Macitentan

Arm Description

10 mg once daily

Outcomes

Primary Outcome Measures

To assess the long-term safety of macitentan in patients with pulmonary arterial hypertension (PAH) beyond treatment in the AC-055-310 study.
Treatment-emergent adverse events (AEs) AEs leading to premature discontinuation of study drug Treatment-emergent serious adverse events (SAEs) Proportion of patients with treatment-emergent ALT and/or AST abnormality (> 3, > 5, and > 8 x ULN) associated or not with total bilirubin > 2 x ULN. Proportion of patients with treatment-emergent hemoglobin abnormality (≦ 100 g/L, and ≦ 80 g/L)

Secondary Outcome Measures

Full Information

First Posted
April 8, 2014
Last Updated
September 19, 2019
Sponsor
Actelion
search

1. Study Identification

Unique Protocol Identification Number
NCT02112487
Brief Title
Extension of the Psychometric Validation Study ORCHESTRA in Patients With PAH
Official Title
An Extension of AC-055-310, a Multi-center, Open-label, Single-arm, Phase 3b Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the French, Italian and Spanish Versions of the PAH-SYMPACT™
Study Type
Interventional

2. Study Status

Record Verification Date
September 2019
Overall Recruitment Status
Completed
Study Start Date
June 23, 2014 (Actual)
Primary Completion Date
September 19, 2018 (Actual)
Study Completion Date
September 19, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Actelion

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Prospective, multi-center, open-label, single-arm, Phase 3b extension study of macitentan in patients with PAH. To assess the long-term safety of macitentan in patients with pulmonary arterial hypertension (PAH) beyond treatment in the AC-055-310 study.
Detailed Description
To assess the long-term safety of macitentan in patients with pulmonary arterial hypertension (PAH) beyond treatment in the AC-055-310 study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pulmonary Arterial Hypertension
Keywords
pulmonary arterial hypertension, PAH-SYMPACT, PAH, psychometric instrument

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
88 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Macitentan
Arm Type
Experimental
Arm Description
10 mg once daily
Intervention Type
Drug
Intervention Name(s)
Macitentan
Other Intervention Name(s)
ACT-064992
Intervention Description
10 mg once daily
Primary Outcome Measure Information:
Title
To assess the long-term safety of macitentan in patients with pulmonary arterial hypertension (PAH) beyond treatment in the AC-055-310 study.
Description
Treatment-emergent adverse events (AEs) AEs leading to premature discontinuation of study drug Treatment-emergent serious adverse events (SAEs) Proportion of patients with treatment-emergent ALT and/or AST abnormality (> 3, > 5, and > 8 x ULN) associated or not with total bilirubin > 2 x ULN. Proportion of patients with treatment-emergent hemoglobin abnormality (≦ 100 g/L, and ≦ 80 g/L)
Time Frame
Baseline to end of treatment visit (around 6 months on average)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Signed informed consent prior to any study-mandated procedure. Patients with PAH who completed the ORCHESTRA study (AC-055-310) as scheduled Women of childbearing potential (as defined below) must: Have a negative serum pregnancy test at Visit 1 (i.e., Visit 4 of study AC 055 310) and agree to perform monthly serum pregnancy tests. Agree to use two reliable methods of contraception in parallel, from Visit 1 until 1 month after study drug discontinuation (see details below). A female is considered to have childbearing potential unless she meets at least one of the following criteria: Previous bilateral salpingo and/or oophorectomy, or hysterectomy. Premature ovarian failure confirmed by a specialist. Pre-pubescence, XY genotype, Turner syndrome, uterine agenesis. Postmenopausal, defined as 12 consecutive months with no menses without an alternative medical cause. Of the two contraceptive methods that must be used, one must be from Group 1, and one must be from Group 2, defined as follows: Group 1: Oral, implantable, transdermal or injectable hormonal contraceptives, intrauterine devices, female sterilization (tubal ligation or non-surgical sterilization, e.g., permanent contraception with Essure procedure), or partner's sterilization (vasectomy). If a hormonal contraceptive is chosen from this group, it must be taken for at least one month prior to enrollment. Alternatively, if the Essure procedure is chosen as a contraceptive method, a hysterosalpingogram must have been performed to confirm correct location of the microinserts and tubal occlusion (as per manufacturer's recommendations). Group 2: Female or male condoms, diaphragm or cervical cap, any of them in combination with a spermicide. Sexual abstinence, rhythm methods, or contraception by the partner alone are not considered as acceptable methods of contraception for this study. Exclusion Criteria: Patients who prematurely discontinued study drug in study AC-055-310. Females who are lactating or pregnant (positive Visit 1 pregnancy test) or plan to become pregnant during the study. AST and/or ALT more than 3 X ULN.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Loïc Perchenet
Organizational Affiliation
Actelion
Official's Role
Study Director
Facility Information:
Facility Name
Hôpital Louis Pradel
City
Bron Cedex
ZIP/Postal Code
69677
Country
France
Facility Name
Hôpital Côte de Nacre
City
Caen
ZIP/Postal Code
14033
Country
France
Facility Name
Hôpital Albert Michallon
City
Grenoble
ZIP/Postal Code
38700
Country
France
Facility Name
CHU de Bicêtre
City
Le Kremlin-Bicêtre
ZIP/Postal Code
94270
Country
France
Facility Name
CHRU Lille - Hôpital Cardiologique
City
Lille
ZIP/Postal Code
59037
Country
France
Facility Name
Hôpital Arnaud de Villeneuve
City
Montpellier
ZIP/Postal Code
34295
Country
France
Facility Name
Hôpitaux de Brabois
City
Nancy
ZIP/Postal Code
54511
Country
France
Facility Name
Hôpital de Haut Levêque
City
Pessac
ZIP/Postal Code
33604
Country
France
Facility Name
Hôpital Pontchaillou
City
Rennes
ZIP/Postal Code
35033
Country
France
Facility Name
Hôpital Charles Nicolle
City
Rouen
ZIP/Postal Code
76031
Country
France
Facility Name
Hôpital Nord
City
Saint-Etienne
ZIP/Postal Code
42227
Country
France
Facility Name
Hôpital Civil
City
Strasbourg
ZIP/Postal Code
67091
Country
France
Facility Name
Hôpital Larrey
City
Toulouse
ZIP/Postal Code
31059
Country
France
Facility Name
Ospedale Sant'Orsola
City
Bologna
ZIP/Postal Code
40138
Country
Italy
Facility Name
A.O.U.C. Careggi
City
Firenze
ZIP/Postal Code
50124
Country
Italy
Facility Name
UOC Immunologia Clinica B-PGRM Centro di Riferimento per la Sclerosi Sistemica
City
Rome
ZIP/Postal Code
00161
Country
Italy
Facility Name
Centro Per La Diagnosi E La Cura Dell'Ipertensione Polmonare
City
Rome
ZIP/Postal Code
00186
Country
Italy
Facility Name
Policlinico G.B. Rossi
City
Verona
ZIP/Postal Code
37134
Country
Italy
Facility Name
Hospital General de Alicante
City
Alicante
ZIP/Postal Code
03010
Country
Spain
Facility Name
Hospital Val Hebron
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
Facility Name
Hospital Clinic
City
Barcelona
ZIP/Postal Code
08036
Country
Spain
Facility Name
Hospital de Cruces
City
Bilbao
ZIP/Postal Code
48903
Country
Spain
Facility Name
Hospital Reina Sofia
City
Córdoba
ZIP/Postal Code
14004
Country
Spain
Facility Name
Hospital Dr Negrin
City
Las Palmas de Gran Canaria
ZIP/Postal Code
35010
Country
Spain
Facility Name
Hospital Universitario Insular Gran Canarias
City
Las Palmas de Gran Canaria
ZIP/Postal Code
35016
Country
Spain
Facility Name
Hospital 12 Octubre
City
Madrid
ZIP/Postal Code
28041
Country
Spain
Facility Name
Hospital La Paz
City
Madrid
ZIP/Postal Code
28046
Country
Spain
Facility Name
Hospital Carlos Haya
City
Malaga
ZIP/Postal Code
29010
Country
Spain
Facility Name
Hospital Son Espases
City
Palma de Mallorca
ZIP/Postal Code
7010
Country
Spain
Facility Name
Hospital de Valdecilla
City
Santander
ZIP/Postal Code
39008
Country
Spain
Facility Name
Hospital Virgen del Rocio
City
Sevilla
ZIP/Postal Code
41013
Country
Spain
Facility Name
Hospita General U. Valencia
City
Valencia
ZIP/Postal Code
46014
Country
Spain

12. IPD Sharing Statement

Links:
URL
http://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003489-15/results
Description
Extension of the psychometric validation study ORCHESTRA in patients with PAH

Learn more about this trial

Extension of the Psychometric Validation Study ORCHESTRA in Patients With PAH

We'll reach out to this number within 24 hrs